Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xue, W.
Right arrow Articles by Ingles, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xue, W.
Right arrow Articles by Ingles, S. A.
[Cancer Research 60, 839-841, February 15, 2000]
© 2000 American Association for Cancer Research

Advances in Brief

Susceptibility to Prostate Cancer: Interaction between Genotypes at the Androgen Receptor and Prostate-specific Antigen Loci1

Wenmei Xue, Ryan A. Irvine, Mimi C. Yu, Ronald K. Ross, Gerhard A. Coetzee and Sue Ann Ingles2

Departments of Preventive Medicine [W. X., M. C. Y., R. K. R., S. A. I.], Molecular Microbiology and Immunology [R. A. I., G. A. C.], and Urology [R. K. R., G. A. C.], University of Southern California, Los Angeles, California 90089

The androgen receptor (AR) regulates gene transcription by binding to androgen response elements in target gene promoters. The prostate-specific antigen (PSA) gene has a polymorphic androgen response element sequence with two alleles, A and G. We hypothesize that allelic differences in AR-driven PSA expression may influence prostate cancer risk. To test this hypothesis, we assayed PSA genotype for 57 prostate cancer cases and 156 controls from our previous pilot study in which prostate cancer risk was associated with the AR "CAG-short" genotype. Odds ratios (ORs) were estimated relating prostate cancer risk to AR and PSA genotypes, singly and in combination. Subjects with the PSA GG genotype were at significantly increased risk for advanced, but not for localized, prostate cancer (OR, 2.90; 95% confidence interval, 1.24–6.78). When cross-classifying subjects by AR and PSA genotypes, subjects with either a CAG-short allele (and not PSA GG) or with the PSA GG genotype (and not CAG-short) had a modest, statistically insignificant increase in prostate cancer risk overall. However, subjects with both a short CAG allele and PSA genotype GG had a more than 5-fold increase in prostate cancer risk (OR, 5.08; 95% confidence interval, 1.59–16.25). All of the ORs were substantially greater for advanced prostate cancer. Studies with larger numbers of advanced cases will be needed to confirm these results. These results indicate that polymorphism in the PSA gene promoter influences prostate cancer risk, and that the allelic variation in promoter activity may be androgen-dependent. Furthermore, these results support a multigenic etiology for prostate cancer.




This article has been cited by other articles:


Home page
 CarcinogenesisHome page
J. Lai, M.-A. Kedda, K. Hinze, R. L.G. Smith, J. Yaxley, A. B. Spurdle, C.P. Morris, J. Harris, and J. A. Clements
PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility
Carcinogenesis, May 1, 2007; 28(5): 1032 - 1039.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
G. Severi, V. M. Hayes, P. Neufing, E. J.D. Padilla, W. D. Tilley, S. A. Eggleton, H. A. Morris, D. R. English, M. C. Southey, J. L. Hopper, et al.
Variants in the Prostate-Specific Antigen (PSA) Gene and Prostate Cancer Risk, Survival, and Circulating PSA.
Cancer Epidemiol. Biomarkers Prev., June 1, 2006; 15(6): 1142 - 1147.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. K. Nam, W. W. Zhang, M. A.S. Jewett, J. Trachtenberg, L. H. Klotz, M. Emami, L. Sugar, J. Sweet, A. Toi, and S. A. Narod
The Use of Genetic Markers to Determine Risk for Prostate Cancer at Prostate Biopsy
Clin. Cancer Res., December 1, 2005; 11(23): 8391 - 8397.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. S. Cicek, X. Liu, G. Casey, and J. S. Witte
Role of Androgen Metabolism Genes CYP1B1, PSA/KLK3, and CYP11{alpha} in Prostate Cancer Risk and Aggressiveness
Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2173 - 2177.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
E. A. Platz, M. F. Leitzmann, N. Rifai, P. W. Kantoff, Y.-C. Chen, M. J. Stampfer, W. C. Willett, and E. Giovannucci
Sex Steroid Hormones and the Androgen Receptor Gene CAG Repeat and Subsequent Risk of Prostate Cancer in the Prostate-Specific Antigen Era
Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1262 - 1269.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. P. Zeegers, L. A.L.M. Kiemeney, A. M. Nieder, and H. Ostrer
How Strong Is the Association Between CAG and GGN Repeat Length Polymorphisms in the Androgen Receptor Gene and Prostate Cancer Risk?
Cancer Epidemiol. Biomarkers Prev., November 1, 2004; 13(11): 1765 - 1771.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
C. A. Borgono, I. P. Michael, and E. P. Diamandis
Human Tissue Kallikreins: Physiologic Roles and Applications in Cancer
Mol. Cancer Res., May 1, 2004; 2(5): 257 - 280.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
C. A. Heinlein and C. Chang
Androgen Receptor in Prostate Cancer
Endocr. Rev., April 1, 2004; 25(2): 276 - 308.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
R. K. Nam, W. W. Zhang, J. Trachtenberg, M. A. S. Jewett, M. Emami, D. Vesprini, W. Chu, M. Ho, J. Sweet, A. Evans, et al.
Comprehensive Assessment of Candidate Genes and Serological Markers for the Detection of Prostate Cancer
Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1429 - 1437.
[Abstract] [Full Text] [PDF]

Home page
 Annals of Clinical & Laboratory ScienceHome page
J. Liu, J.-S. Zhang, C. Y. F. Young, and P. C. Kao
Polymorphisms of Prostate-Specific Antigen Gene Promoter: Determination From Cord Blood Collected on Filter Paper
Ann. Clin. Lab. Sci., October 1, 2003; 33(4): 429 - 434.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. D. Cramer, B.-L. Chang, A. Rao, G. A. Hawkins, S. L. Zheng, W. N. Wade, R. T. Cooke, L. N. Thomas, E. R. Bleecker, W. J. Catalona, et al.
Association Between Genetic Polymorphisms in the Prostate-Specific Antigen Gene Promoter and Serum Prostate-Specific Antigen Levels
J Natl Cancer Inst, July 16, 2003; 95(14): 1044 - 1053.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. K. Nam, W. W. Zhang, J. Trachtenberg, E. Diamandis, A. Toi, M. Emami, M. Ho, J. Sweet, A. Evans, M. A.S. Jewett, et al.
Single Nucleotide Polymorphism of the Human Kallikrein-2 Gene Highly Correlates With Serum Human Kallikrein-2 Levels and in Combination Enhances Prostate Cancer Detection
J. Clin. Oncol., June 15, 2003; 21(12): 2312 - 2319.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
T. R. Rebbeck
Inherited Genotype and Prostate Cancer Outcomes
Cancer Epidemiol. Biomarkers Prev., October 1, 2002; 11(10): 945 - 952.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
C. Chen, N. Lamharzi, N. S. Weiss, R. Etzioni, D. A. Dightman, M. Barnett, D. DiTommaso, and G. Goodman
Androgen Receptor Polymorphisms and the Incidence of Prostate Cancer
Cancer Epidemiol. Biomarkers Prev., October 1, 2002; 11(10): 1033 - 1040.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. Gsur, M. Preyer, G. Haidinger, T. Zidek, S. Madersbacher, G. Schatzl, M. Marberger, C. Vutuc, and M. Micksche
Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk
Carcinogenesis, October 1, 2002; 23(10): 1647 - 1651.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. Xu, D. A. Meyers, D. A. Sterling, S. L. Zheng, W. J. Catalona, S. D. Cramer, E. R. Bleecker, and J. Ohar
Association Studies of Serum Prostate-specific Antigen Levels and the Genetic Polymorphisms at the Androgen Receptor and Prostate-specific Antigen Genes
Cancer Epidemiol. Biomarkers Prev., July 1, 2002; 11(7): 664 - 669.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
G. G. Giles, G. Severi, R. Sinclair, D. R. English, M. R. E. McCredie, W. Johnson, P. Boyle, and J. L. Hopper
Androgenetic Alopecia and Prostate Cancer: Findings from an Australian Case-Control Study
Cancer Epidemiol. Biomarkers Prev., June 1, 2002; 11(6): 549 - 553.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
K. A. Nelson and J. S. Witte
Androgen Receptor CAG Repeats and Prostate Cancer
Am. J. Epidemiol., May 15, 2002; 155(10): 883 - 890.
[Abstract] [Full Text] [PDF]

Home page
 J. Gerontol. A Biol. Sci. Med. Sci.Home page
A. M. Matsumoto
Andropause: Clinical Implications of the Decline in Serum Testosterone Levels With Aging in Men
J. Gerontol. A Biol. Sci. Med. Sci., February 1, 2002; 57(2): M76 - 99.
[Full Text]

Home page
 Hum Mol GenetHome page
V. Nwosu, J. Carpten, J. M. Trent, and R. Sheridan
Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease
Hum. Mol. Genet., October 1, 2001; 10(20): 2313 - 2318.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Zitzmann, M. Brune, B. Kornmann, J. Gromoll, S. von Eckardstein, A. von Eckardstein, and E. Nieschlag
The CAG Repeat Polymorphism in the AR Gene Affects High Density Lipoprotein Cholesterol and Arterial Vasoreactivity
J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4867 - 4873.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. L. Goode, J. L. Stanford, M. A. Peters, M. Janer, M. Gibbs, S. Kolb, M. D. Badzioch, L. Hood, E. A. Ostrander, and G. P. Jarvik
Clinical Characteristics of Prostate Cancer in an Analysis of Linkage to Four Putative Susceptibility Loci
Clin. Cancer Res., September 1, 2001; 7(9): 2739 - 2749.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
W.-M. Xue, G. A. Coetzee, R. K. Ross, R. Irvine, L. Kolonel, B. E. Henderson, and S. A. Ingles
Genetic Determinants of Serum Prostate-specific Antigen levels in Healthy Men from a Multiethnic Cohort
Cancer Epidemiol. Biomarkers Prev., June 1, 2001; 10(6): 575 - 579.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.